Will Your Genetics Predict How Much Weight You Lose on a GLP-1?
The largest genetic study of GLP-1 medication response ever conducted was published in Nature in April 2026. Here's what it found and what it means for patients choosing between GLP-1 options.
The Study: 27,885 Real-World Patients
Researchers at 23andMe analyzed genetic and self-reported outcome data from 27,885 adults who had taken GLP-1 receptor agonists. Unlike clinical trials, which study carefully selected participants under controlled conditions, this study captures what happens in the real world — across diverse genetic backgrounds, health conditions, and lifestyle factors.
Three Key Findings
1. A GLP1R Variant Predicts Better Response
A specific change in the GLP1R gene — the gene that encodes the receptor these drugs target — was significantly associated with greater weight loss. Each copy of the beneficial variant produced an additional 0.76 kg (about 1.7 pounds) of weight loss. Since you inherit two copies of each gene, someone with two copies of this variant might lose roughly 3.4 extra pounds compared to someone without it.
This may sound modest, but it's meaningful at a population level. It confirms that individual biology — not just adherence or diet — explains some of the variability in outcomes.
2. A GIPR Variant Predicts Nausea (Tirzepatide Only)
Variation in the GIPR gene predicted nausea and vomiting in patients taking tirzepatide (Zepbound/Mounjaro) but not in patients taking semaglutide (Wegovy/Ozempic). This makes mechanistic sense: tirzepatide activates both GLP-1 and GIP receptors, while semaglutide only activates GLP-1.
For patients who experienced severe nausea on tirzepatide, this finding suggests switching to semaglutide might reduce side effects — not because semaglutide is milder, but because their specific genetic profile makes them sensitive to GIP receptor activation.
3. Effectiveness Varies by Ancestry and Diabetes Status
GLP-1 medications were most effective for weight loss in people of European ancestry, with lower effectiveness in Latino and African American populations. Patients with Type 2 diabetes experienced about 2.87 fewer percentage points of BMI loss compared to non-diabetic patients.
Can You Test for These Variants?
23andMe is already offering GLP-1 response information through its Total Health platform. If you're a 23andMe customer, you may be able to access information about your GLP1R and GIPR variants.
However, most physicians aren't yet using genetic testing to guide GLP-1 prescribing. The clinical utility isn't established — knowing your variant status doesn't yet change the standard treatment algorithm. That said, the field is evolving rapidly, and pharmacogenomic GLP-1 prescribing may become standard practice within a few years.
Practical Takeaways for Today
Poor response doesn't mean failure. If you lost less than expected on one GLP-1, consider switching to a different one. The different receptor profiles (GLP-1 only vs. GLP-1/GIP dual) may produce different results in your body.
Severe nausea on tirzepatide? A switch to semaglutide may help if your nausea is driven by GIPR sensitivity rather than GLP-1 receptor activation.
Give it adequate time. Most clinical trials measured outcomes at 68-72 weeks. If you're only a few months in, you may not have reached your maximum response yet.